Clinical Trials Browser

Active not recruiting × Neoplasms × Nivolumab × Clear all

Neoplasms, Stomach Neoplasms

NCT04336241 2026-02-27

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Phase 1 Active not recruiting

36 enrolled

BreastDermatologicGastrointestinalThoracic

Uveal Melanoma, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms

NCT04078295 2026-02-10

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Phase 1/2 Active not recruiting

125 enrolled

Tumor-Agnostic

Neoplasms

NCT06880549 2026-02-05

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

Phase 1 Active not recruiting

57 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT06764771 2025-12-17

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Phase 1 Active not recruiting

437 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Colorectal Neoplasms

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Phase 1 Active not recruiting

463 enrolled

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT04095208 2025-10-02

CONGRATS

Phase 2 Active not recruiting

67 enrolled

Sarcoma

Tertiary Lymphoid Structures, Neoplasm Metastasis, Neoplasms, Sarcoma

NCT03937219 2025-09-10

COSMIC-313

Phase 3 Active not recruiting

855 enrolled 12 charts

Genitourinary

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT03470922 2025-09-09

RELATIVITY-047

Phase 2/3 Active not recruiting

714 enrolled 17 charts 2 FDA

Dermatologic

Melanoma, Neoplasms

NCT02099058 2025-08-14

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

237 enrolled

Tumor-Agnostic

Neoplasms

NCT03522246 2025-06-24

ATHENA

Phase 3 Active not recruiting

1,097 enrolled 26 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT05180799 2025-06-15

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Phase 1/2 Active not recruiting

320 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

NCT05888831 2025-06-11

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Phase 1/2 Active not recruiting

100 enrolled

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Triple Negative Breast Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Phase 1 Active not recruiting

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT04300244 2024-02-29

NIPU

Phase 2 Active not recruiting

118 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Lung Neoplasms, Mesothelioma, Neoplasms

Clinical Trials

ILUSTRO

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

CONGRATS

COSMIC-313

RELATIVITY-047

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

ATHENA

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

NIPU